Preparation and characterization of 10-hydroxycamptothecin loaded nanostructured lipid carriers

Drug Development and Industrial Pharmacy

Volumn 34, Issue 5, 2008, Pages 465-471

  Liu, Kai ^a   Sun, Jin ^a   Wang, Yongjun ^a   He, Yuan ^a   Gao, Kun ^a   He, Zhonggui ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

10 hydroxycamptothecin; In vitro release; Incorporation efficiency; Lyophilization; Nanostructured lipid carriers

Indexed keywords

10 HYDROXYCAMPTOTHECIN; DRUG CARRIER; GLYCEROL BEHENATE; LACTONE; LUTROL F 68; MANNITOL; MIGLYOL; NANOMATERIAL; POLIDOCANOL; POLOXAMER; TREHALOSE;

ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG RELEASE; DRUG SYNTHESIS; EMULSION; FREEZE DRYING; HUMAN; LASER DIFFRACTION; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; PHYSICAL CHEMISTRY; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CALORIMETRY, DIFFERENTIAL SCANNING; CAMPTOTHECIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG COMPOUNDING; FREEZE DRYING; INJECTIONS, INTRAVENOUS; LACTONES; MICROSCOPY, ELECTRON, TRANSMISSION; NANOSTRUCTURES; PARTICLE SIZE; POLOXAMER; POLYETHYLENE GLYCOLS; SOLUBILITY; SURFACE-ACTIVE AGENTS; ULTRASONICS; X-RAY DIFFRACTION;

EID: 45849089162     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040701662230     Document Type: Article

References (31)

1. Abdelwahed, W., Degobert, G., Stainmesse, S., & Fessi, H. (2006). Freeze-drying of nanoparticles: Formulation, process and storage considerations. Adv. Drug Deliv. Rev., 58, 1688-1713.
2. Allen, C., Maysinger, D., & Eisenberg, A. (1999). Nano-engineering block copolymer aggregates for drug delivery. Colloids Surf. B Biointerfaces, 16, 3-27.
3. Arica-Yegin, B., Benoit, J. P., & Lamprecht, A. (2006). Paclitaxel-loaded lipid nanoparticles prepared by solvent injection or ultrasound emulsification. Drug Dev. Ind. Pharm., 32(9), 1089-1094.
4. Carbonero, R., & Supko, J. (2002). Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res., 8, 641-661.
5. Cortesi, R., Esposito, E., Maietti, A., Menegatti, E., & Nastruzzi, C. (1997). Formulation study for the antitumor drug camptothecin: Liposomes, micellar solutions and a microemulsion. Int. J. Pharm., 159, 95-103.
6. Ertl, B., Platzer, P., Wirth, M., & Gabor, F. (1999). Poly(D,L-lactic-co-glycolic acid) microspheres for sustained delivery and stabilization of camptothecin. J. Controlled Rel., 61, 305-317.
7. Garcia-Fuentes, M., Aolores, M. J., & Torres, D. (2005). Design and characterization of a new drug nanocarrier made from solid-liquid lipid mixtures. J. Colloid Interface Sci., 285(2), 590-598.
8. Gref, R., Minamitake, Y., Peracchia, M. T., Trebetskoy, V. S., Torchilin, V. P., & Langer, R. (1994). Biodegradable long-circulating polymeric nanospheres. Science, 263, 1600-1603.
9. Hatefi, A., & Amsden, B. (2002). Camptothecin delivery methods. Pharm. Res., 19, 1389-1399.
10. Hung, C. F., Fang, C. L., Liao, M. H., & Fang, J. Y. (2007). The effect of oil components on the physicochemical properties and drug delivery of emulsions: Tocol emulsion versus lipid emulsion. Int. J. Pharm., 335, 193-202.
11. Jaxel, C., Kohn, K. W., Wani, M. C., Wall, M. E., & Prommier, Y. (1989). Structure-acticvity study of the actions of camptothecin derivatives on mammalian topoisomerase I: Evidence for a specific receptor site and for a relation to antitumor activity. Cancer Res., 49, 1465-1469.
12. Joshi, M., & Patravale, V. (2006). Formulation and evaluation of Nanostructured Lipid Carrier (NLC)-based gel of Valdecoxib. Drug Dev. Ind. Pharm., 32(8), 911-918.
13. Konan, Y. N., Gurny, R., & Allémann, E. (2002). Preparation and characterization of sterile and freeze-dried sub-200 nm nanoparticles. Int. J. Pharm., 233, 239-252.
14. Lee, M. K., Lim, S. J., & Kim, C. K. (2007). Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials, 28, 2131-2146.
15. Liu, J., Zhu, J., Du, Z., & Qin, B. (2005). Preparation and pharmacokinetic evaluation of Tashinone.II. A solid lipid nanoparticles. Drug Dev. Ind. Pharm., 31(6), 551-556.
16. Malzert-Freon, A., Vrignaud, S., Saulnier, P., Lisowski, V., Benoit, J. P., & Rault, S. (2006). Formulation of sustained release nanoparticles loaded with a tripentone, a new anticancer agent. Int. J. Pharm., 320, 157-164.
17. Müller, R. H., Madar, K., & Gohla, S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm., 50, 161-177.
18. Müller, R. H., Mehnert, W., Lucks, J. S., Schwarz, C., zur Muhlen, A., Weyhers, H., Freitas, C., & Ruhl, D. (1995). Solid lipid nanoparticles-an alternative collidal carrier system for controlled drug delivery. Eur. J. Pharm. Biopharm., 41, 62-69.
19. Müller, R. H., Radtke, M., & Wissing, S. A. (2002a). Nanostructured lipid matrices for improved microencapsulation of drugs. Int. J. Pharm., 242, 121-128.
20. Müller, R. H., Radtke, M., & Wissing, S. A. (2002b). Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev., 54, S131-S155.
21. O'Leary, J., & Muggia, F. M. (1998). Camptothecins: A review of their development and schedules of administration. Eur. J. Cancer, 34, 1500-1508.
22. Potmesil, M. (1994). Camptothecins: From bench research to hospital wards. Cancer Res., 54, 1431-1439.
23. Pouton, C. W. (2000). Lipid formulations for oral administration of drugs: Non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. Eur. J. Pharm. Sci., 11, S93-S98.
24. Schubert, M. A., & Müller-Goymann, C. C. (2005). Characterisation of surface-modified solid lipid nanoparticles (SLN): Influence of lecithin and nonionic emulsifier. Eur. J. Pharm. Biopharm., 61, 77-86.
25. Shenderova, A., Burke, T., & Schwendeman, S. (1997). Stabilization of 10-hydroxycamptothecin in poly(lactide-co-glycolide) microsphere delivery vehicles. Pharm. Res., 14, 1406-1414.
26. Tong, W., Wang, L., & D'Souza, M. J. (2003). Evaluation of PLGA microspheres as delivery system for antitumor angent-camptothecin. Drug Dev. Ind. Pharm., 29(3), 745-756.
27. Wall, M. E., Wani, M. C., Cook, C. E., Palmer, K. H., McPhail, A. T., & Sim, G. A. (1966). Plant antitumor agents. I. The isolation and structureof camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminate. J. Am. Chem. Soc., 88, 3888-3890.
28. Yang, S. C., & Zhu, J. B. (2002). Preparation and characterization of camptothecin solid lipid nanoparticles. Drug Dev. Ind. Pharm., 28(3), 265-274.
29. Zhang, C., Ding, Y., Yu, L. L., & Ping, Q. N. (2007). Polymeric micelle systems of hydroxycamptothecin based on amphiphilic N-alkyl-N- trimethyl chitosan derivatives. Colloids Surf. B. Biointerfaces, 55, 192-199.
30. Zhang, L. Y., Yang, M., Wang, Q., Li, Y., Guo, R., Jiang, X., Yang, C. Z., & Liu, B. R. (2007). 10-hydroxycamptothecin loaded nanoparticles: Preparation and antitumor activity in mice. J. Control. Rel., 119, 153-162.
31. Zhang, J., Xuan, T., Parmar, M., Ma, L., Ugwu, S., Ali, S., & Ahmad, I. (2004). Development and characterization of a novel liposome-based formulation of SN-38. Intl. J. Pharm., 270, 93-107.